These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 31657017)

  • 21. Defining the best cut-off value for lymphopenia in diffuse large B cell lymphoma treated with immuno-chemotherapy.
    Bari A; Tadmor T; Sacchi S; Marcheselli L; Cox C; Liardo EV; Pozzi S; Benyamini N; Avivi I; Ferrari A; Baldini L; Falorio S; Gobbi P; Federico M; Polliack A
    Br J Haematol; 2014 Oct; 167(1):133-6. PubMed ID: 24797533
    [No Abstract]   [Full Text] [Related]  

  • 22. Comparison of R-CVP with R-CHOP for very elderly patients aged 80 or over with diffuse large B cell lymphoma.
    Arakaki H; Nakazato T; Osada Y; Ito C; Aisa Y; Mori T
    Ann Hematol; 2017 Jul; 96(7):1225-1226. PubMed ID: 28508175
    [No Abstract]   [Full Text] [Related]  

  • 23. Monoclonal gammopathy of undetermined significance and risk of venous thromboembolism.
    Gregersen H; Nørgaard M; Severinsen MT; Engebjerg MC; Jensen P; Sørensen HT
    Eur J Haematol; 2011 Feb; 86(2):129-34. PubMed ID: 20942842
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Developments over the last 60 years in diffuse large B-cell lymphomas.
    Linch D
    Br J Haematol; 2020 Nov; 191(4):552-557. PubMed ID: 33190261
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Gaucher disease and monoclonal gammopathy: a report of 17 cases and impact of therapy.
    Grosbois B; Rose C; Noël E; Serratrice Cde R; Dobbelaere D; Gressin V; Chérin P; Hartmann A; Javier RM; Clerson P; Hachulla E; Jaussaud R;
    Blood Cells Mol Dis; 2009; 43(1):138-9. PubMed ID: 19427246
    [No Abstract]   [Full Text] [Related]  

  • 26. Oncologist volume and outcomes in older adults diagnosed with diffuse large B cell lymphoma.
    Huntington SF; Hoag JR; Zhu W; Wang R; Zeidan AM; Giri S; Podoltsev NA; Gore SD; Ma X; Gross CP; Davidoff AJ
    Cancer; 2018 Nov; 124(21):4211-4220. PubMed ID: 30216436
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Characteristics and prognostic factors for head and neck non-Hodgkin's lymphoma in Chinese patients.
    Wang J; Cai CP; He SF; Wang SL
    J Laryngol Otol; 2013 Jul; 127(7):699-704. PubMed ID: 23738972
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Monoclonal gammopathy and neuropathy.
    Ramchandren S; Lewis RA
    Curr Opin Neurol; 2009 Oct; 22(5):480-5. PubMed ID: 19625962
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The immunoglobulin isotype matters in diffuse-large-B-cell lymphoma with serum paraproteinaemia.
    Cox MC; Di Napoli A; Scarpino S; Ruco L
    Ann Hematol; 2015 Apr; 94(4):681-2. PubMed ID: 25193355
    [No Abstract]   [Full Text] [Related]  

  • 30. Peripheral blood lymphocyte/monocyte ratio predicts outcome in follicular lymphoma and in diffuse large B-cell lymphoma patients in the rituximab era.
    Belotti A; Doni E; Bolis S; Rossini F; Casaroli I; Pezzatti S; Pogliani EM; Pioltelli PE
    Clin Lymphoma Myeloma Leuk; 2015 Apr; 15(4):208-13. PubMed ID: 25468321
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The significance of pretreatment anemia in the era of R-IPI and NCCN-IPI prognostic risk assessment tools: a dual-center study in diffuse large B-cell lymphoma patients.
    Troppan KT; Melchardt T; Deutsch A; Schlick K; Stojakovic T; Bullock MD; Reitz D; Beham-Schmid C; Weiss L; Neureiter D; Wenzl K; Greil R; Neumeister P; Egle A; Pichler M
    Eur J Haematol; 2015 Dec; 95(6):538-44. PubMed ID: 25677782
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dose-Dense Rituximab-CHOP versus Standard Rituximab-CHOP in Newly Diagnosed Chinese Patients with Diffuse Large B-Cell Lymphoma: A Randomized, Multicenter, Open-Label Phase 3 Trial.
    Li X; Huang H; Xu B; Guo H; Lin Y; Ye S; Yi J; Li W; Wu X; Wang W; Zhan H; Xie D; Peng J; Cao Y; Pu X; Guo C; Hong H; Wang Z; Fang X; Zhou Y; Lin S; Liu Q; Lin T
    Cancer Res Treat; 2019 Jul; 51(3):919-932. PubMed ID: 30282447
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Secondary central nervous system relapse in diffuse large B cell lymphoma in a resource limited country: result from the Thailand nationwide multi-institutional registry.
    Wudhikarn K; Bunworasate U; Julamanee J; Lekhakula A; Chuncharunee S; Niparuck P; Ekwattanakit S; Khuhapinant A; Norasetthada L; Nawarawong W; Makruasi N; Kanitsap N; Sirijerachai C; Chansung K; Wong P; Numbenjapon T; Prayongratana K; Suwanban T; Wongkhantee S; Praditsuktavorn P; Intragumtornchai T;
    Ann Hematol; 2017 Jan; 96(1):57-64. PubMed ID: 27752821
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dose-intensified CHOP with rituximab (R-Double-CHOP) followed by consolidation high-dose chemotherapies for patients with advanced diffuse large B-cell lymphoma.
    Kurita D; Miura K; Nakagawa M; Ohtake S; Sakagami M; Uchino Y; Takahashi H; Kiso S; Hojo A; Kodaira H; Yagi M; Hirabayashi Y; Kobayashi Y; Iriyama N; Kobayashi S; Hatta Y; Kura Y; Sugitani M; Takei M
    Int J Hematol; 2015 Jun; 101(6):585-93. PubMed ID: 25776837
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Retrospective analysis of the clinical features and prognostic factors of 370 patients with advanced-stage diffuse large B-cell lymphoma].
    Han Y; Qin Y; He XH; Yang JL; Liu P; Zhang CG; Zhou LQ; Zhou SY; Gui L; Song YW; Sun Y; Shi YK
    Zhonghua Zhong Liu Za Zhi; 2018 Jun; 40(6):456-461. PubMed ID: 29936773
    [No Abstract]   [Full Text] [Related]  

  • 36. A clinically based prognostic index for diffuse large B-cell lymphoma with a cut-off at 70 years of age significantly improves prognostic stratification: population-based analysis from the Danish Lymphoma Registry.
    Gang AO; Pedersen M; d'Amore F; Pedersen LM; Jensen BA; Jensen P; Møller MB; Mourits-Andersen HT; Pedersen RS; Klausen TW; de N Brown P
    Leuk Lymphoma; 2015; 56(9):2556-62. PubMed ID: 25629994
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The BCL-2 biomarker in the era of molecular diagnosis of diffuse large B-cell lymphoma.
    Dunleavy K; Staudt LM; Wilson WH
    Leuk Lymphoma; 2007 Jun; 48(6):1061-3. PubMed ID: 17577765
    [No Abstract]   [Full Text] [Related]  

  • 38. Clinicopathologic significance of tumor microenvironment CD11c, and FOXP3 expression in diffuse large B-cell lymphoma patients receiving rituximab, cyclophosphamide, anthracycline, vincristine, and prednisone (R-CHOP) combination chemotherapy.
    Lee S; Kim DH; Oh SY; Kim SY; Koh MS; Lee JH; Lee S; Kim SH; Kwak JY; Pak MG; Ju MH; Kim HJ; Jeong JS
    Korean J Intern Med; 2017 Mar; 32(2):335-344. PubMed ID: 26968188
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Diffuse large B-cell non-Hodgkin's lymphoma: ESMO clinical recommendations for diagnosis, treatment and follow-up.
    Tilly H; Dreyling M;
    Ann Oncol; 2008 May; 19 Suppl 2():ii67-9. PubMed ID: 18456774
    [No Abstract]   [Full Text] [Related]  

  • 40. Monoclonal gammopathy and cold agglutinin disease in non-Hodgkin's lymphoma.
    Pascali E
    Eur J Haematol; 1996; 56(1-2):114-5. PubMed ID: 8599986
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.